Don't Jump to Kerendia for Diabetic Kidney Disease
October 2021
Kerendia (finerenone) will be a new Rx for patients with chronic kidney disease (CKD) due to type 2 diabetes.
It's the first "nonsteroidal mineralocorticoid receptor antagonist"...and is approved to slow kidney disease progression and improve CV outcomes in these patients.
Kerendia is thought to limit fibrosis and inflammation in the kidneys and heart...by blocking effects of aldosterone.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote